http://www.courtagen.com/resource-center-pressreleases.htmCourtagen News© 2012 {CompanyNameHere} All Rights Reserved5/9/2012 12:00:00 AM5News14448http://www.courtagen.comhttp://www.courtagen.com/Collateral/Images/English-US/ico-1.gifhttp://www.courtagen.com/e998b390-cb03-4495-b155-cf5730b54b07/resource-center-newsroom-detail.htmFri, 25 Nov 2011 00:00:00 GMTe998b390-cb03-4495-b155-cf5730b54b07Elizabethtitle changehttp://www.courtagen.com/5e4ab7a4-d1b6-4c35-84d0-6460c64e190c/resource-center-newsroom-detail.htmWed, 18 Jan 2012 00:00:00 GMT5e4ab7a4-d1b6-4c35-84d0-6460c64e190cElizabeth HollandBased on its recent analysis of the clinical diagnostic tools market, Frost & Sullivan recognizes Courtagen Life Sciences, Inc. with the 2011 North American Frost & Sullivan Award for New Product Innovation.http://www.courtagen.com/dc970fa5-809c-4f6e-b761-227628de0b1b/resource-center-newsroom-detail.htmThu, 02 Feb 2012 00:00:00 GMTdc970fa5-809c-4f6e-b761-227628de0b1bElizabethPartners to Develop Quantitative Point -of-Care Surveillance and Detection Assay for High Threat Biological Agents and Infectious Diseases http://www.courtagen.com/99906d6f-ef71-41a2-bc29-cb489ad49bfd/resource-center-newsroom-detail.htmThu, 09 Feb 2012 00:00:00 GMT99906d6f-ef71-41a2-bc29-cb489ad49bfdElizabethCourtagen Life Sciences, Inc. (“Courtagen”), a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced that it has entered into a strategic collaboration with Avaxia Biologics, Inc. (“Avaxia”) to develop an assay that will streamline the development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident. The combined effort will focus on addressing the critical need to quickly and accurately identify the impact of Avaxia’s oral antibody therapy in animal models and, ultimately, in patients.http://www.courtagen.com/4a40f760-e79a-4e0e-a81a-6e9a1452d30f/resource-center-newsroom-detail.htmWed, 29 Feb 2012 00:00:00 GMT4a40f760-e79a-4e0e-a81a-6e9a1452d30fe hollandCourtagen Life Sciences, Inc., a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced the introduction of their first genetic tests using next generation sequencing (NGS) technology, propriety bioinformatics platform and highly annotated, analytic capabilities to diagnose mitochondrial disease in children and adults. The Courtagen tests, which are designed to be highly sensitive, efficient and comprehensive, will address the significant need for a quicker, less invasive and more reliable diagnostic tool for this patient population.http://www.courtagen.com/8b3c44b7-086e-4b87-9b26-bc5545ebab22/resource-center-newsroom-detail.htmThu, 29 Mar 2012 00:00:00 GMT8b3c44b7-086e-4b87-9b26-bc5545ebab22http://www.courtagen.com/06c1c409-7038-4cc5-b00a-3d49e8cbfcb4/resource-center-newsroom-detail.htmWed, 09 May 2012 00:00:00 GMT06c1c409-7038-4cc5-b00a-3d49e8cbfcb4